Better affordability of high-quality medicines

We drive early market entries at best prices

Get a reliable, flexible, and cost-efficient supply!

We strongly believe that our high-quality medicines should be affordable for all patients irrespective of their income level. That´s why we strive for these two goals:

  1. Achieving an earliest possible generic market entry for our customers
    AET is well known for its highly rated research & development competence, quality excellence, and regulatory expertise – being the foundation for a constant track record of first-to-file dossiers. A professional project management and an outstanding intellectual property guidance are further important pillars to ensure that our first-to-market strategies are successful.
  2. Driving efficiency in our supply chains to offer best possible prices
    We drive efficiency by keeping our supply chains simple and reaching economies of scale in our own manufacturing sites. This results in best value for money for our customers. Modern supply chain solutions and a lean management approach ensure that our products reach the right place in the right condition and quantity at an affordable price on time. All our pharmaceutical production plants are equipped with up-to-date technologies, highly qualified professionals, and highest safety standards. This ensures full compliance with Good Manufacturing Practice (GMP). Apart from the most important governmental approvals, our sites are periodically inspected by leading pharmaceutical companies.

How we drive better affordability of high-quality medicines

Our success factors for early market entries at best prices

highly rated regulatory expertise

R&D and quality assurance excellence

constant generation of first-to-file-dossiers

efficiency-driven supply chain management

highly rated regulatory expertise

R&D and quality assurance excellence

constant generation of first-to-file-dossiers

efficiency driven supply chain management

economies of scale in own manufacturing sites

reliable and flexible supply

professional project management

outstanding intellectual property guidance

economies of scale in own manufacturing sites

reliable and flexible supply

professional project management

outstanding intellectual property guidance

Driving efficiency in our two own manufacturing sites

Delorbis Pharmaceuticals – a part of the Tiefenbacher Group

Small batch as well as high-volume productions made in Europe

DELORBIS manufacturing facilities on Cyprus have been designed to accommodate the bulk production and primary and secondary packaging operations of non-sterile oral solid dosage forms (tablets, capsules, and powder suspensions for reconstitution). The production and packaging lines are equipped with sophisticated technology from the first manufacturing step throughout to the last packaging step and are flexible to manage small batch as well as high-volume productions. Thanks to our highly competent personnel as well as the state-of-the-art equipment available in the quality control laboratory, we can also offer to our partners:

  • EU batch testing and release of pharmaceutical products
  • ICH stability studies at long-term, intermediate, and accelerated conditions for all zones (incl. zone IVb)
  • many analytical laboratory services (e. g. chemical testing of raw materials and drug products, method validation/transfer, comparative dissolution profiles) and support from our experienced analysts
  • technology transfer
  • import/storage/warehousing

Find out more on: http://www.delorbispharma.eu/

AET Laboratories manufacturing site

Our advanced, FDA approved manufacturing site in India

With AET LABS, we own a second state-of-the-art manufacturing site, located in Hyderabad, India. Featuring a GMP-compliant environment on a 32.000 m² sized plant, AET LABS is equipped with the most modern technologies for manufacturing, testing, packing, warehousing, and releasing solid oral dosage forms. Quality control is an integral part of AET LABS´ manufacturing process. The facility holds the ISO 14001:2014 and ISO 18001:2015 certifications and was successfully inspected by the German BGV, the Russian MIT, and the US FDA authorities.

We are best practice

Successful day-one-launch of Posaconazole

In 2019 AET successfully launched the first generic product of Posaconazole, a therapeutically equivalent version of the originator product Noxafil®. Studies have demonstrated the satisfactory quality of the product and its bioequivalence to the reference product. Posaconazole is effectively used for the treatment of several fungal infections. With this first-to-market entry in nine European countries, AET achieved nameable savings for the international health care systems and enabled millions of patients a better affordable access to this life-improving treatment. Following our global market entry approach, a launch in about 60 further international countries is already in progress.
Posaconazole has been developed and manufactured in TIEFENBACHER´s own laboratory and manufacturing sites under strictest safety and quality guidelines. An efficiency-driven supply chain approach as well as our highly rated development and regulatory expertise were important pillars for this successful day-one-launch.

We are happy to help, get in touch.

Do not hesitate to get in touch for more information about driving better affordability of our high-quality pharmaceuticals. Our experts are always available to help.